An interventional study of chatbot-mediated supportive care intervention in Institutionalization, Elderly and Mental Health, sponsored by Universitat Autonoma de Barcelona. Recruiting at 2 sites in Spain. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Universitat Autonoma de Barcelona · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Psychological Well-Being with a site in Spain — 36 open to participants now, 47 under way, none of them phase 3. Psychological Well-Being · Spain.
Among the 107 studies in Psychological Well-Being with a site in Spain, this one is the 70th largest by planned enrollment of the 86 interventional ones that give a count, is one of 16 that started in 2026, is one of 85 with no phase, reaches primary completion later than 17 of the 46 other live ones, and was the 85th registered.
2,208 studies on the registry are indexed under Psychological Well-Being; 730 are open to participants now.
Browse Psychological Well-Being studies →36 of the 107 studies in Psychological Well-Being with a site in Spain are open now. Recruiting first, the newest first:
Francisco Antonio Nieto Escámez · Sites in Spain
Ages 60+ · Healthy volunteers
Svenja Taubner · Sites in Spain, Germany, Lithuania and 1 more country
Ages 8+ · Healthy volunteers
Hospital Virgen del Puerto · Sites in Spain
Ages 18+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages 18+ · Women only
University of Castilla-La Mancha · Sites in Spain
Ages 18–24 · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 403 Psychological Well-Being studies recruiting now, 223 (55%) set no upper age limit and 155 (38%) stop at 75 or younger; 121 take children under 18; 206 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 16 started in 2026.
This study's planned enrollment of 55 is below the median of 110 across 1,808 interventional studies indexed under Psychological Well-Being.
Median enrollment 127 across the 86 interventional studies, 200 across the 21 observational. Of the 51 that completed or were terminated, 1 (2%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 107 have an industry lead sponsor. The 10 most frequent:
Universitat Autonoma de Barcelona is the lead sponsor of 10 studies on the registry; 5 are open to participants now.
Universitat Autonoma de Barcelona has 3 studies filed under Psychological Well-Being — fewer than ten, so there is no comparison to draw.
17 of the studies in Psychological Well-Being with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07925736Universidad Miguel Hernandez de ElcheALAS PROPIAS: BMGIM for Professionals Working in Intimate Partner Machista Violence Services | 2026-11-30 |
| NCT07925723Universidad Miguel Hernandez de ElcheALAS PROPIAS: Music Therapy for Women Experiencing Machista Violence in Intimate Partner Relationships | 2026-11-30 |
| NCT07655063Hospital Clinic of BarcelonaThe Green Room: Virtual Nature for Mental Well-being in the Acute Psychiatry Ward | 2026-12 |
| NCT06796946University of HuelvaDeprescription of Antidepressants in Primary Care (DAPriCare) | 2026-12 |
| NCT06450730Maimónides Biomedical Research Institute of CórdobaEffectiveness of a Combined mHealth-CBT Psychological Intervention to Improve Psychological Well-Being in Young Patients With T1D | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 107 studies in Psychological Well-Being with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Aurora is an interdisciplinary project evaluating a chatbot-mediated supportive care intervention designed to promote emotional expression, autobiographical meaning-making, identity processes, and emotional well-being through guided narrative reconstruction. The Aurora system provides a structured, person-centered storytelling process supported by generative AI and human facilitation. Under the supervision of a trained facilitator (licensed mental health professional), participants engage in guided reminiscence and storytelling sessions to co-create a personalized "life book." The chatbot is not a diagnostic or treatment tool; rather, it is intended to support emotional expression, narrative reconstruction, and recovery-oriented processes. The study includes three non-randomized arms implemented sequentially: (1) a single-session arm of healthy adults focused on acceptability, usability, and emotional safety; (2) a four-hour intervention arm of adults with DSM-5 diagnosed mental disorders in residential care; and (3) a four-hour intervention arm of healthy older adults aged 65 years and older. Quantitative outcomes assess affect, mental well-being, and recovery-related constructs. Additional measures include usability, satisfaction, and qualitative feedback. Ecological momentary assessment (EMA) is conducted in Arms 2 and 3.
Pre-human development (in silico; not part of the clinical trial):
Prior to human participation, the Aurora system underwent an in-silico preparatory phase focused on content coherence and emotional safety using synthetic user profiles. Simulated interactions were reviewed by licensed mental health professionals to identify potential safety concerns and inform iterative refinements of the supportive narrative process. This preparatory work did not involve human participants and is not part of the clinical trial.
Human participants (clinical trial):
The study uses a sequential, non-randomized, three-arm interventional design with a total anticipated sample of 55 participants.
Arm 1: Healthy adults (single-session arm; n=20) Following informed consent, participants complete a single guided interaction with Aurora to generate a brief personal narrative. Outcomes include pre-session expectations, pre-post session affect (I-PANAS-SF), perceived usefulness and user experience, usability (System Usability Scale, SUS), satisfaction, and qualitative feedback.
Arm 2: Adults with DSM-5 diagnosed mental disorder in residential care (4-hour intervention arm; n=15) Following informed consent, participants complete four guided sessions over two weeks (two sessions per week, 1 hour per session). Outcomes include pre-session expectations, pre-post session affect (I-PANAS-SF) for each session, perceived usefulness and user experience, usability (SUS), satisfaction, qualitative feedback, and pre-post intervention self-report measures of mental well-being and recovery-related constructs. Ecological momentary assessment (EMA) is conducted during the 1-week pre-intervention period, the 2-week intervention period, and the 1-week post-intervention follow-up period.
Arm 3: Healthy older adults (aged 65 years and older; 4-hour intervention arm; n=20) Following informed consent, participants complete two guided sessions over two weeks (one session per week, 2 hours per session). Outcomes include pre-session expectations, pre-post session affect (I-PANAS-SF) for each session, perceived usefulness and user experience, usability (SUS), satisfaction, qualitative feedback, and pre-post intervention self-report measures of mental well-being and recovery-related constructs. Ecological momentary assessment (EMA) is conducted during the 1-week pre-intervention period, the 2-week intervention period, and the 1-week post-intervention follow-up period.
Data security and compliance:
All interactions occur in a secure professional environment. Textual data are pseudonymized during transcription and fully anonymized at the end of the project. Optional audio recordings are stored on encrypted offline devices and deleted after integration into the participant's life book. The study complies with applicable data protection and regulatory frameworks, including GDPR (EU 2016/679), LOPDGDD 3/2018, the EU AI Act (2024/1689), and institutional ethics guidelines.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Arm 1: Healthy Adults (Single-Session Intervention)
Age 18 years or older at screening.
Sufficient ability to read and understand Spanish to follow study instructions and complete questionnaires.
Ability to engage in a brief guided interaction and complete self-report measures.
Able and willing to provide written .
---
Arm 2: Adults with Diagnosed Mental Disorder in Residential Care (4-hour Intervention)
Age 18 years or older at screening.
Currently residing in a participating long-term mental health residential care facility and expected to remain there for the duration of the intervention and post-assessment period.
Documented diagnosis of a mental disorder according to DSM-5 criteria, confirmed by the treating clinician.
Minimal clinical stability at baseline, defined as all of the following:
Clinically stable in the judgment of the treating clinician.
No requirement for acute psychiatric hospitalization or crisis intervention in the previous 4 weeks.
Clinical Global Impression - Improvement (CGI-I) score between 3 and 5 inclusive during the 4 weeks prior to enrollment, indicating relative clinical stability.
Sufficient ability to understand spoken and written Spanish to participate in study procedures.
Ability to engage in guided interaction and provide feedback.
Able and willing to provide informed consent; when applicable, provision of legal guardian consent plus participant assent.
Willingness to participate in all study procedures.
---
Arm 3: Healthy Older Adults (≥65 Years; 4-hour Intervention)
Age 65 years or older at screening.
No self-reported diagnosis of a serious mental disorder (for example, psychotic disorder or bipolar disorder).
Sufficient ability to read and understand Spanish to participate in study procedures.
Adequate cognitive and communication abilities to engage in guided interaction and complete questionnaires.
Able and willing to provide written informed consent.
---
Exclusion Criteria
Arm 1: Healthy Adults
Current acute medical or psychiatric condition that would compromise safe participation or data validity.
Moderate or high acute suicide or self-harm risk at screening.
Significant cognitive, communication, or comprehension impairment that would interfere with participation.
Explicit refusal to participate.
---
Arm 2: Adults with Diagnosed Mental Disorder in Residential Care
Current acute psychiatric decompensation requiring crisis-level care.
Moderate or high acute suicide or self-harm risk at screening or baseline.
High risk of emotional harm from autobiographical life review, defined as treating clinician judgment that narrative or reminiscence work is due to one or more of the following:
Severe clinical destabilization within the past 3 months.
Trauma-related re-experiencing symptoms.
Marked dissociative symptoms.
Inability to provide , with no legal representative available when required, or lack of participant assent when applicable.
Significant cognitive, communication, or comprehension impairment without available supports.
Explicit refusal to participate.
Imminent discharge or transfer that would prevent completion of the intervention or post-assessment.
---
Arm 3: Healthy Older Adults
Self-reported diagnosis of a serious mental disorder (for example, psychotic disorder or bipolar disorder).
Moderate or high acute suicide or self-harm risk at screening.
Current acute medical or psychiatric condition that would compromise safe participation.
Significant cognitive, communication, or comprehension impairment that would interfere with participation.
Explicit refusal to participate.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy adults complete one Aurora session (single exposure) for platform refinement and usability assessment.
Behavioral: chatbot-mediated supportive care intervention
Adults (aged ≥18 years) with a DSM-5 diagnosed mental disorder, residing in long-term mental health residential care facilities, complete a four-session guided narrative program over two weeks (two sessions per week, 1 hour per session) with facilitation by a licensed mental health professional.
Behavioral: chatbot-mediated supportive care intervention
Healthy older adults (aged ≥65 years), with no self-reported diagnosis of a serious mental disorder, complete a two-session guided narrative program over two weeks (one session per week, 2 hours per session) with facilitation by a licensed mental health professional.
Behavioral: chatbot-mediated supportive care intervention
Aurora is a guided narrative reconstruction chatbot combining structured storytelling and reminiscence with an AI-based conversational system and support from a trained facilitator. Participants co-create a personalized life narrative ("life book") with written content and optional audio contributions (with explicit consent). Sessions occur in a secure professional environment and are supervised by licensed mental health professionals to ensure emotional safety. Aurora is not a diagnostic tool and is intended to promote emotional expression, recovery-oriented processes, and emotional well-being. The intervention is delivered in structured guided sessions. Arm 1 receives a single-session version for refinement and usability assessment, whereas Arms 2 and 3 receive a 4-hour intervention delivered over two weeks. The total intervention dose is equivalent across Arms 2 and 3. Session structure differs to accommodate participant characteristics.
Also known as: Aurora, Aurora AI-Assisted Narrative Reconstruction Chatbot
Positive Affect (I-PANAS-SF - Positive Affect subscale-pre-post session change)
Positive affect will be assessed using the Positive Affect (PA) subscale of the International Positive and Negative Affect Schedule - Short Form (I-PANAS-SF). Participants will rate their affect "right now." The endpoint is the change in PA from immediately before to immediately after each session across all treatment arms. Higher scores indicate higher positive affect.
Time frame: Change from immediately before to immediately after each session, up to 2 weeks.
Negative Affect (I-PANAS-SF - Negative Affect subscale - pre-post session change)
Negative affect will be assessed using the Negative Affect (NA) subscale of the International Positive and Negative Affect Schedule - Short Form (I-PANAS-SF). Participants will rate their affect "right now." The endpoint is the change in NA from immediately before to immediately after each session across all treatment arms. Higher scores indicate higher negative affect.
Time frame: Change from immediately before to immediately after each session, up to 2 weeks.
Positive Affect (I-PANAS-SF - Positive Affect subscale - baseline to 1-week follow-up change)
Positive affect will be assessed using the Positive Affect (PA) subscale of the I-PANAS-SF. Participants will rate their affect "over the past week." The endpoint is the change in PA from baseline to immediately post-intervention in Arms 2 and 3. Higher scores indicate higher positive affect.
Time frame: Change from baseline at 1 week after end of intervention.
Negative Affect (I-PANAS-SF - baseline to 1-week follow-up change)
Negative affect will be assessed using the Negative Affect (NA) subscale of the I-PANAS-SF, adapted to assess affect over the past week. The endpoint is the change in NA from baseline (pre-intervention) to 1-week follow-up after completion of the intervention in Arms 2 and 3. Higher scores indicate higher negative affect.
Time frame: Change from baseline at 1 week after end of intervention.
Mental well-being (WEMWBS)
Mental well-being will be assessed using the Warwick-Edinburgh Mental Well-being Scale (WEMWBS; total score). Higher scores indicate greater mental well-being. The endpoint is change from baseline at 1 week after end of intervention in Arms 2 and 3.
Time frame: Change from baseline at 1 week after end of intervention.
Recovery-related outcomes aligned with CHIME framework
Recovery-related outcomes will be assessed using an ad hoc self-report measure aligned with the CHIME framework. The measure includes six constructs (3 items each): social connectedness, hope, self-concept clarity, valued living, general self-efficacy, and self-esteem. A total composite score will be computed. Higher scores indicate more favorable recovery-related outcomes. The endpoint is the change from baseline (pre-intervention) to 1-week follow-up after completion of the intervention in Arms 2 and 3.
Time frame: Change from baseline at 1 week after end of intervention.
Usability (System Usability Scale, SUS)
Usability will be assessed using the System Usability Scale (SUS). The SUS is a 10-item self-report measure of perceived usability. Total scores range from 0 to 100, with higher scores indicating better perceived usability. In Arm 1, the SUS will be administered immediately after the single session. In Arms 2 and 3, the SUS will be administered at follow-up, 1 week after the end of the intervention.
Time frame: Immediately after session (Arm 1); 1 week after end of intervention (Arms 2 and 3)
User experience and satisfaction
User experience and satisfaction will be assessed using study-specific self-report items covering expectations, perceived usefulness, and satisfaction/opinion. In Arm 1, this measure will be administered immediately after the single session. In Arms 2 and 3, it will be administered at follow-up, 1 week after the end of the intervention.
Time frame: Immediately after session (Arm 1); 1 week after end of intervention (Arms 2 and 3)
Ecological Momentary Assessment (EMA)
Ecological momentary assessment (EMA) will be conducted in Arms 2 and 3. Participants will complete brief assessments twice daily across three predefined periods: (1) a 1-week pre-intervention baseline period, (2) the 2-week intervention period, and (3) a 1-week post-intervention follow-up period. EMA will include brief momentary items assessing affect, valued action, self-efficacy/empowerment, connectedness/hope, and psychological flexibility, capturing real-time (momentary) experiences.
Time frame: Twice daily from 1 week before intervention to 1 week after end of intervention.
Plan to share: No — Individual participant data will not be shared due to the sensitive nature of the data, which include mental health information and autobiographical narrative content from a vulnerable population. Data use is restricted to the approved study objectives under the conditions of the ethics committee approval and applicable data protection regulations (GDPR).
No publications or documents are linked to this record.
Started Feb 2026 (actual). Primary completion is estimated for Apr 2026, 1 month after the start.
Of 1,274 non-industry interventional studies with no phase under Psychological Well-Being, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 34. This study's planned 1 month is below that.
Counting every sponsor, half of 1,317 studies reached it within 16 months; a quarter within 7 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitat Autonoma de Barcelona